

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA52: Summary of Cholinesterase Activity
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 06/22/2026
Time Report Requested: 11:51:09
Lab: Battelle

Study Number: C11042B-01
Study Sex: Both
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.9
Stat Version: 2023.02.27S

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA52: Summary of Cholinesterase Activity

Test Compound: Triphenyl Phosphate (TPHP)

CAS Number: 115-86-6

Date Report Requested: 06/22/2026

Time Report Requested: 11:51:09

Lab: Battelle

F1 Male: PND 28 Interim Cohort

		Treatment Groups (ppm)					
	Phase Day	0	30	100	300	1000	3000
Acetylcholinesterase in Brain (U/g)	PND 28	3.2 ± 0.2 (5) **	3.1 ± 0.2 (5)	3.1 ± 0.1 (5)	2.5 ± 0.1 (5) *	2.9 ± 0.2 (5) *	2.3 ± 0.2 (5) **
Percent of Control			95.7	95.4	76.2	89.9	70.5
Butyrylcholinesterase in Brain (U/g)	PND 28	2.8 ± 0.1 (5) **	2.7 ± 0.2 (5)	2.7 ± 0.1 (5)	2.3 ± 0.1 (5)	2.6 ± 0.2 (5)	2.2 ± 0.1 (5) *
Percent of Control			96.5	95.0	81.9	93.1	78.2

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA52: Summary of Cholinesterase Activity

Test Compound: Triphenyl Phosphate (TPHP)

CAS Number: 115-86-6

Date Report Requested: 06/22/2026

Time Report Requested: 11:51:09

Lab: Battelle

F1 Female: PND 28 Interim Cohort

		Treatment Groups (ppm)					
	Phase Day	0	30	100	300	1000	3000
Acetylcholinesterase in Brain (U/g)	PND 28	2.8 ± 0.2 (5)	2.9 ± 0.2 (5)	2.9 ± 0.3 (5)	2.7 ± 0.2 (5)	3.3 ± 0.1 (5)	2.3 ± 0.2 (5)
Percent of Control			104.7	102.4	94.9	116.6	80.8
Butyrylcholinesterase in Brain (U/g)	PND 28	2.5 ± 0.1 (5)	2.7 ± 0.1 (5)	2.5 ± 0.2 (5)	2.5 ± 0.2 (5)	3.0 ± 0.0 (5)	2.2 ± 0.2 (5)
Percent of Control			109.6	99.2	99.1	120.9	89.7

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA52: Summary of Cholinesterase Activity

Test Compound: Triphenyl Phosphate (TPHP)

CAS Number: 115-86-6

Date Report Requested: 06/22/2026

Time Report Requested: 11:51:09

Lab: Battelle

F1 Male: Neurobehavioral Cohort

		Treatment Groups (ppm)					
	Phase Day	0	30	100	300	1000	3000
Acetylcholinesterase in Blood (U/L)	PND 138 - 142	237.8 ± 14.6 (4)	196.7 ± 33.3 (4)	192.1 ± 26.6 (5)	183.7 ± 10.6 (5)	243.1 ± 56.8 (4)	199.9 ± 13.8 (5)
Percent of Control			82.7	80.8	77.2	102.2	84.1
Butyrylcholinesterase in Plasma (U/L)	PND 138 - 142	49.4 ± 11.4 (5) **	57.0 ± 11.1 (5)	48.0 ± 6.5 (5)	28.2 ± 6.7 (5)	17.2 ± 3.8 (5) *	7.2 ± 1.2 (5) **
Percent of Control			115.5	97.3	57.1	34.7	14.6

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA52: Summary of Cholinesterase Activity
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 06/22/2026
Time Report Requested: 11:51:09
Lab: Battelle

F1 Female: Neurobehavioral Cohort

		Treatment Groups (ppm)					
	Phase Day	0	30	100	300	1000	3000
Acetylcholinesterase in Blood (U/L)	PND 138 - 142	149.8 ± 31.9 (5)	143.7 ± 38.4 (4)	153.5 ± 23.3 (5)	213.6 ± 21.7 (4)	231.0 ± 34.6 (4)	158.0 ± 20.7 (4)
Percent of Control			96.0	102.5	142.6	154.2	105.4
Butyrylcholinesterase in Plasma (U/L)	PND 138 - 142	572.0 ± 40.5 (5) **	490.8 ± 46.1 (5)	519.5 ± 70.6 (5)	407.4 ± 45.7 (5) *	241.1 ± 47.2 (5) **	66.8 ± 16.0 (4) **
Percent of Control			85.8	90.8	71.2	42.2	11.7

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA52: Summary of Cholinesterase Activity
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 06/22/2026
Time Report Requested: 11:51:09
Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

PND = Postnatal Day

Data not reported was due to results that did not meet assay acceptance criteria and insufficient volume for repeat analysis.

For the endpoint "Acetylcholinesterase in Blood" data were obtained from assays of red blood cell erythrocyte membrane preparations.

**** END OF REPORT ****